Who is sponsoring NCT03775681?

NCT03775681 is sponsored by M.D. Anderson Cancer Center.

What condition does NCT03775681 study?

NCT03775681 studies Bile Duct Disorder, Endocrine Pancreas Disorder.

Is NCT03775681 still recruiting?

NCT03775681 is currently completed. Last updated 27 April 2021.

Are results published for NCT03775681?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-04-27 · How we verify

NCT03775681

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders

Completed NA Results posted Last updated 27 April 2021

What this trial tests

NA trial testing Endoscopic Retrograde Cholangiopancreatography in Bile Duct Disorder in 33 participants. Completed in 20 April 2020.

Timeline

16 January 2019

Primary endpoint
20 April 2020

20 April 2020

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	33
Start date	16 January 2019
Primary completion	20 April 2020
Estimated completion	20 April 2020
Sites	1 location across United States

Drugs / interventions tested

Endoscopic Retrograde Cholangiopancreatography
Interview
Laryngeal Mask Airway

Conditions studied

Bile Duct Disorder — all drugs for Bile Duct Disorder →
Endocrine Pancreas Disorder — all drugs for Endocrine Pancreas Disorder →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Bile Duct Disorder or Endocrine Pancreas Disorder. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

The Number of Participants With Overall Success of ERCP With LMA Gastro Primary · Up to 3 months

Successful completion of ERCP with the LMA® Gastro™

Group	Value	95% CI
LMA® Gastro™	28

Gastroenterologist and Anesthesiologist Satisfaction With the LMA® Gastro™ Secondary · Up to 3 months

Surveys for gastroenterologist and anesthesiologist satisfaction with the Laryngeal Mask Airway (LMA) Gastro contain items measured on a 10-point Likert scale with 1 reflecting strong disagreement and 10 strong agreement. Mean scores and standard deviations will be used to provide summaries for each survey item. Summaries will be stratified by gastroenterologist and anesthesiologist. Paired differences in survey items between gastroenterologist and anesthesiologist scores will be summarized using descriptive statistics and 95% CIs.

Discordance

Group	Value	95% CI
LMA® Gastro™	3.45	0 – 100

Concordance

Group	Value	95% CI
LMA® Gastro™	96.55	0 – 100

Sponsor's own description

This trial determines the feasibility of Laryngeal Mask Airway Gastro (Laryngeal Mask Airway) when used on patients who are undergoing endoscopic retrograde cholangiopancreatography for pancreas and bile duct disorders. Laryngeal Mask Airway is a device that helps patients breathe while they are asleep during procedures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Endoscopic Retrograde Cholangiopancreatography

Trials testing the same drug.

NCT07064980 — ERCP Versus PTBD for Severe Acute Cholangitis Caused by Bile Duct Stones · NA · completed
NCT04740164 — A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP · NA · completed
NCT03820544 — SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstr · NA · terminated
NCT06388525 — Post-ERCP Cholecystectomy. How ERCP and ERCP-related Variables Effect the Outcomes? · completed

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03775681 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 27 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03775681.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing